Seeking Alpha
 

Vermillion, Inc. (VRML)

- NASDAQ
  • Wed, Mar. 18, 8:38 AM
    | Comment!
  • Mon, Mar. 16, 12:45 PM
    | Comment!
  • Dec. 23, 2014, 12:45 PM
    | Comment!
  • Jul. 10, 2013, 12:45 PM
    Midday top 10 gainers: NEON +25%. INO +22%. NUS +15%. SKBI +14%. PCYC +13%. VRML +13%. BMJ +13%. MCP +13%. ADHD +11%. SPEX +11%.
    Midday top 10 Losers: ADVS -25%. NEO -17%. PME -14%. XNY -11%. CREG -11%. ALJ -9%. TRR -8%. RAX -8%. BRLI -8%. LCNB -8%.
    | Comment!
  • May. 15, 2013, 4:47 PM
    More on Vermillion (VRML): Q1 beats on the top line with higher OVA1 product sales, but misses on its EPS. Net losses increased as one-time items, including costs related to the delayed 2012 annual shareholder meeting held in March, a proxy contest and CEO transition all weighed on margins. Shares -18.7% AH.
    | Comment!
  • May. 15, 2013, 4:24 PM
    Vermillion (VRML): Q1 EPS of -$0.17 misses by $0.02. Revenue of $328K beats by $28.K. Shares -15.4% AH. (PR)
    | Comment!
  • May. 14, 2013, 2:00 PM
    Vermillion (VRML -2.3%) reverses earlier gains to trade lower today, after saying it's closed its 8M share private placement, with net proceeds of $11.8M after expenses. The company also issued warrants for 12.5M shares of stock at $1.46 per share, which could give VRML an additional $18.3M in proceeds, bringing the total gross proceeds to $31.5M.
    | 1 Comment
  • May. 10, 2013, 12:52 PM
    Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
    Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%.
    | Comment!
  • May. 9, 2013, 2:55 PM
    Vermillion (VRML +39%) soars today after reporting earlier that Oracle Investment Management and other investors will make an initial investment of $13.2M by purchasing 8M shares of the company's stock.  VRML will also issue 12.5M warrants with a strike price of $1.46 for $18.3M in proceeds, bringing the total gross investment to $31.5M. Proceeds will be used to increase test sales and improve reimbursement for OVA1, as well as to expand into new markets and advance next-generation ovarian cancer diagnostic tests.
    | Comment!
  • May. 9, 2013, 12:46 PM
    Midday top 10 gainers: TRMD +94%. OPTT +42%. VRML +32%. AFFY +28%. TSLA +27%. XOMA +26%. GMCR +25%. CTRP +24%. OWW +23%. CHYR +19%.
    Midday top 10 losers: LPSN -34%. PZZI -33%. RAX -26%. KEM -25%. NSYS -23%. MNOV -22%. WG -20%. GV -18%. ORBT -16%. OFIX -16%.
    | Comment!
  • Apr. 17, 2013, 9:21 AM
    Vermillion (VRML) +29.4% premarket after the developer of diagnostic tests signs a cooperative research and development agreement with the U.S. Army. A two-phase study will investigate the cost-benefit profile of OVA1 testing as a presurgical standard of care in women with pelvic masses, and assess OVA1 clinical utility in a managed care setting.
    | Comment!
  • Apr. 17, 2013, 9:12 AM
    Premarket gainers: VRML +29%. ACUR +26%. OCZ +18%. CUR +9%. ALKS +9%. ABMD +9%. ASML +6%.
    Losers: EOPN -29%. INWK -25%. CXW -15%. MHR -12%. ZGNX -11%. TXT -9%. CRUS -7%. VRNG -6%.
    | 1 Comment
  • Feb. 20, 2013, 7:32 PM
    Vermillion (VRML): Q4 EPS of -$0.09 beats by $0.03. Revenue of $1.14M (+32% Y/Y) beats by $0.2M. Shares -1.5% AH. (PR)
    | Comment!
  • Nov. 29, 2012, 12:45 PM
    Midday top 10 gainers: HGSH +48%. ACUR +46%. PBM +42%. BLOX +36%. OCZ +24%. THQI +23%. AXR +22%. CARV +21%. TELK +20%. OBCI +16%.
    Midday top 10 Losers: LQDT -17%. VRML -13%. ATEA -12%. LZB -11%. HITK -10%. KSS -9%. LAS -9%. BKS -9%. ABCD -8%. PIP -7%.
    | Comment!
  • Nov. 28, 2012, 12:45 PM
    Midday top 10 gainers: VRML +34%. SHS +32%. GMCR +24%. SPMD +18%. TROV +17%. GPOR +16%. IDIX +15%. TSL +15%. KCG +14%. AXR +12%.
    Midday top 10 Losers: UTI -24%. CLUB -21%. CFNB -16%. GENE -15%. TFM -14%. CBAK -13%. SBGI -12%. DWCH -13%. NFEC -11%. CAP -9%.
    | 2 Comments
  • Nov. 12, 2012, 4:57 PM
    More on Vermillion (VRML): Q3 beats bottom line consensus on lower-than-anticipated losses. Revenue was flat on a Y/Y basis, while earnings got a big boost from better cost controls. Operating expenses decreased by nearly half as compared to the prior year period, driven by lower clinical trial costs, fewer legal expenses and ongoing cost containment initiatives. Shares +7.5% AH.
    | Comment!
Visit Seeking Alpha's
VRML vs. ETF Alternatives
Company Description
Vermillion Inc is engaged in discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases.